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in this stage, referred to by clinicians 
as Mild ad, individuals’ short-term 
memory is clearly impaired and new 
symptoms emerge, such as difficulty 
speaking and understanding language, 
alongside frequent mood swings. Here, 
formal diagnosis of ad becomes much 
more likely, forcing patients to endure 
the anticipation of their looming 
dementia. Moreover, the disease also 
begins to take a physical and emotional 
toll on patients’ loved ones, as assis-
tance with some aspects of daily living 
becomes necessary. Mild ad typi-
cally lasts 1-2 years before worsening 
symptoms qualify it as Moderate ad, 
when individuals experience severe 
memory loss and exhibit behaviors that 
can be emotionally traumatizing to 
all involved, such as rambling speech, 
delusions, and uninhibited actions. in 
the process, patients are robbed of their 
identities and their families are forced 
to watch helplessly. in its final stage, 
Severe ad, patients suffer a near com-
plete loss of memory and the ability to 
communicate or process information; 
they lose their mobility and, eventually, 
even their capacity to swallow. From 
diagnosis to death, the disease’s dura-
tion typically lasts 8-10 years and, sadly, 
we lack effective therapeutics to halt, let 
alone reverse, the disease’s progression. 
as a budding cell biologist exiting grad-
uate school in 2007 and in the process 
of discerning the next step in my career, 
this heartbreaking reality prompted me 
to seek research opportunities to con-
tribute to the fight against this dreaded 
disease. this led to a research fellowship 
at the Massachusetts general Hospital 
alzheimer’s disease research Center, 
where i was inspired by a diverse and 
collaborative community of physicians, 
scientists, and philanthropists who are 
devoted to battling ad. we have much 
to learn about its underlying pathology 
and effective approaches for treatment,  
but the commitment and spirit of the 
ad research community gives us  
hope that one day we can eradicate  
the disease. 
Tracking the etiology 
of AD—from clinical 
dementia to plaques  
and tangles to beta- 
amyloid aggregation
given its brutality and prevalence 
(more than 5 million people currently 
live with ad, a figure that is pro-
jected to rise to 13.5 million by 2050), 
enormous resources have been put into 
biomedical research focused on under-
standing and treating ad. effective 
treatments have yet to be established; 
nonetheless we have learned a great deal 
about the pathology that takes place in 
the ad brain. the earliest insights were 
provided over a century ago by german 
physician alois alzheimer (1864-
1915), after whom the disease is named 
(Figure 1). when his patient, auguste 
deter (a woman who was suffering 
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alzheimer’s disease (ad) is ruthless. at its earliest stage (Pre-Clinical ad), it begins wreaking havoc on the brains of patients 
without causing clinical symptoms, leaving them 
unaware that they need medical counsel. as the  
disease progresses, symptoms start to manifest as 
episodes of short-term memory impairment, which  
are often dismissed as normal cognitive decline  
during aging. if not dismissed, these episodes can 
instill fright and uncertainty about what the future 
holds. this period, referred to as Mild Cognitive 
impairment (MCi) can last months or years before 
symptoms worsen to a degree that triggers alarm. 
Figure 1. Dr. Alois Alzheimer (1864-1915) and his patient Auguste Deter (1850-1906).  
Source: Uncredited photos from Wikimedia Commons.
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Figure 2. Coronal brain sections of healthy brain versus AD brain that has undergone severe 
atrophy (left) and microscopic analysis of AD brain tissue highlighting the hallmark lesions that 
develop in AD brain—plaques and tangles (right). Sources: National Institute of Health, Wikimedia 
Commons; LaDu Neurodegeneration Research Lab, University of Illinois Chicago.
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from dementia) died in 1906, Dr. 
Alzheimer performed an autopsy on her 
brain and identified three abnormalities 
that to this day are regarded as hall­
mark features of AD pathology. On a 
macroscopic level, Alzheimer observed 
that Deter’s brain had undergone severe 
atrophy (Figure 2, left), which we now 
know results from extensive neuro­
degeneration (the death of brain cells 
called neurons) that occurs during AD. 
Neuron activities are central to the 
control and execution of virtually all 
human behaviors including those lost in 
AD (memory, language and commu­
nication skills, information processing, 
and mobility). His discovery provided a 
clear causal link between brain atrophy 
and the clinical symptoms that take 
place during the disease. On a micro­
scopic level, Alzheimer determined that 
Deter’s brain also contained two abnor­
mal lesions referred to as plaques and 
tangles (Figure 2, right). Importantly, 
these observations alone suggested 
that Alzheimer’s Disease results from 
the accumulation of toxic plaques and 
tangles in the brain that cause neuro­
degeneration and the clinical symptoms 
associated with the disease. Testing this 
hypothesis, however, required answers 
to several fundamental questions that 
Alzheimer could not address due to  
the technological limitations of his 
time. These questions included: What 
are plaques and tangles composed of? How 
do they form? Why do they form in brains  
of AD patients? Are plaques and tangles  
the toxic agents that cause the neuro degen­
eration during AD? Or, conversely, might 
they be an inconsequential side effect  
of the disease process?
Perhaps surprisingly, addressing these 
fundamental questions awaited 80 
years of progress in our understanding 
of biology, development of research 
technology, and national commitment 
to combating AD. Nevertheless, when 
these three developments converged in 
the 1980s, they ignited an explosion of 
AD research that has continued to pre­
sent day. The explosion began in 1984 
when researchers identified the core 
component of plaques—the protein 
beta­amyloid (aka, amyloid­beta and 
Aß)—which set the stage for research­
ers to determine where it comes from 
and how it forms plaques. Subsequent 
studies showed that beta­amyloid is 
first produced in brain cells as part of 
a larger, membrane­embedded pro­
tein called APP (Figure 3), which is 
regularly cleaved by enzymes, releas­
ing beta­amyloid into the surrounding 
brain tissue. Critically, in Alzheimer’s 
Disease the released beta­amyloid  
From diagnosis to death,  
the disease’s duration typically 
lasts 8­10 years and, sadly, we  
lack effective therapeutics to  
halt, let alone reverse, the  
disease’s progression.
Figure 3. Schematic depiction of the process of amyloid plaque formation. Sources: National Institute on Aging and Wikispaces.
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readily aggregates into insoluble  
deposits—plaques. Parallel to these 
studies on beta­amyloid, researchers 
also determined that the core compo­
nent of tangles is a protein called tau, 
which was already known to play an 
essential role in maintaining the health 
of neurons through binding (adher­
ing to) and stabilizing structures called 
microtubules. As depicted in Figure 4, 
microtubules are elongated structures 
inside neurons that provide stability to 
neuronal extensions (called neurites),  
a function that is indispensable to  
neuronal health and function. During 
AD, tau dissociates from microtubules 
and aggregates into insoluble deposits 
—tangles—resulting in the disassembly 
of microtubules and consequent degen­
eration of neurites.
This characterization of beta­amyloid 
and tau aggregation into plaques and 
tangles, respectively, raised several new 
questions about AD pathology, many of 
which are still being investigated today. 
One that is central not only to our 
understanding of the disease, but  
also to the development of AD thera­
peutics is this: Can the root cause of AD  
be attributed to either beta­amyloid aggre­
gation into plaques or tau aggregation into 
tangles? If one of these events can be 
identified as the root cause, then we  
can focus resources on therapeutics that 
can intervene in that event. In other 
words, if beta­amyloid aggregation  
represents the triggering event in  
AD, then blocking beta­amyloid  
aggregation may represent the most 
promising approach to treating AD 
patients; likewise, if tau aggregation  
is the causative event in AD, then 
blocking it may prove more effective. 
Major progress toward answering this 
question started in the early 1990s, 
stemming from genetic studies on  
several families whose members exhib­
ited a rare, inherited form of AD  
called familial Alzheimer’s Disease  
(or FAD). FAD differs from the most 
common form of AD (called sporadic 
AD because it arises sporadically in 
population without a clear genetic 
cause) in that it is passed on through 
generations of a family due to the 
inheritance of a genetic mutation. 
Starting in the 1990s, researchers began 
performing genetic analyses on families 
with FAD in an attempt to identify the 
mutation(s) responsible for the disease. 
Since then, more than 200 mutations 
have been discovered. Strikingly, all of 
these mutations are located within one 
of two genes: the gene that produces 
APP (see Figure 3); or the one that 
produces the protein presenilin, a key 
enzyme that cleaves APP to produce 
beta­amyloid. Moreover, experimen­
tal analysis of these mutations dem­
onstrated that they cause a common, 
critical effect in the brain: they increase 
beta­amyloid aggregation into plaques. 
These discoveries, along with studies 
proving that plaques and smaller  
aggregates of beta­amyloid are toxic  
to neurons, led researchers to formulate 
Figure 4. How microtubules disintegrate with Alzheimer’s Disease. Sources: Alzheimer’s Disease Education and Referral Center, National Institute on Aging 
and Wikimedia Commons.
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beta-amyloid aggregation in ad.  
in doing so, three fundamental  
“paths” that contribute to beta-amyloid 
aggregation in sporadic ad have  
been defined.
First, while cleavage of aPP occurs 
continuously in brain tissue, the rate 
of cleavage can vary and is affected by 
numerous factors that we now know 
contribute to ad pathology. More 
specifically, factors that increase the 
rate of aPP cleavage cause increased 
rates of beta-amyloid production, 
leading to its accumulation, which can 
in turn drive its aggregation (Figure 
6a). Second, to balance the ongoing 
production of beta-amyloid, brain cells 
have concurrent processes to continu-
ously remove or “clear” it from tissue. 
thus, factors that decrease the rate 
of beta-amyloid clearance can also 
cause its accumulation and aggrega-
tion (Figure 6B). Lastly, while no clear 
genetic cause for sporadic ad has been 
identified, one gene—apolipoprotein e 
(or, apoe)—has been demonstrated to 
inf luence a person’s chance of develop-
ing the disease. the apoe gene exists 
in population as three variants referred 
to as apoe2, apoe3, and apoe4, all of 
which produce a protein that transports 
cholesterol throughout the brain. in 
1993, it was discovered that individuals 
who inherit apoe4 have a 5-10 times 
greater risk of developing ad. in addi-
tion, brains of ad patients carrying 
the amyloid cascade hypothesis (Figure 5), 
the most significant guiding force in 
ad research for the past 20 years. 
the amyloid hypothesis posits that 
alzheimer’s disease is triggered by the 
accumulation of small beta-amyloid 
aggregates and larger plaques that exert 
pathological stress on the surround-
ing brain tissue. this stress, in turn, 
causes additional pathology, including 
tangle formation, leading to widespread 
neuronal dysfunction and, ultimately, 
dementia. importantly, while inher-
itance of the aPP and presenilin 
mutations explain why beta-amyloid 
aggregates in the brains of patients with 
Fad, the cause of beta-amyloid aggre-
gation in sporadic ad is not yet fully 
understood. given the fact that sporadic 
ad constitutes greater than 95% of all 
cases, determining its cause is a major 
focus of ongoing research.
Three paths to beta-amyloid 
aggregation in sporadic 
Alzheimer’s Disease
in 1992, an important discovery was 
made that now frames our grow-
ing understanding of beta-amyloid 
pathology. the discovery was that 
although beta-amyloid represents the 
major toxic agent in ad, its presence  
in the brain is not limited to individuals 
with the disease. rather, beta-amyloid  
is produced in the brains of all indi-
viduals—young and old, healthy and 
diseased—through continuous synthe-
sis and cleavage of aPP (see Figure 3).  
this is important because it dismisses 
simple explanations for ad etiol-
ogy. researchers need to pursue more 
nuanced explanations for the cause of 
given its brutality and prevalence 
(more than 5 million people 
currently live with ad, a figure 
that is projected to rise to 13.5 
million by 2050), enormous 
resources have been put into 
biomedical research focused on 
understanding and treating ad. 
Figure 5. The amyloid cascade hypothesis. Adapted from Figure 1 in Karran et al., “The Amyloid 

















apoe4 exhibit significantly more beta-
amyloid plaques than those of patients 
carrying apoe2 or apoe3, suggesting 
that apoe4 promotes ad by increasing 
beta-amyloid aggregation. Subsequent 
studies have demonstrated that, rather 
than affecting beta-amyloid genera-
tion or clearance, apoe4 protein binds 
and enhances its aggregation (Figure 
6C). From patient to patient, it is likely 
that one or a combination of these 
three paths to beta-amyloid aggrega-
tion—increased production, decreased 
clearance, and inheritance of apoe4—
explains the onset of ad.
Treating Alzheimer’s 
Disease—Where are we? 
Where aren’t we?
alongside research directed at charac-
terizing the cause(s) of ad, enormous 
effort has also been focused on develop-
ing compounds with which to treat or 
prevent the disease. Based on the amy-
loid cascade hypothesis, the therapeutic 
approaches considered most promising 
entail administering medications that 
will block or reverse beta-amyloid 
aggregation in the brain. Of the com-
pounds generated and tested to date, 
many have been designed using our 
knowledge of the three paths to beta-
amyloid aggregation. For example, 
several compounds have been created 
that inhibit the enzymes responsible for 
aPP cleavage (see Figure 6a), whereas 
others enhance beta-amyloid clearance 
(see Figure 6B). a third class of com-
pounds has been designed to interfere 
with beta-amyloid aggregation directly 
(see Figure 6C). Sadly, however, while 
many of these compounds have shown 
promise in laboratory models of ad, 
we have yet to establish one that has 
proved effective as a medication in 
human clinical trials (due either to 
insufficient reduction in beta-amyloid 
aggregation or to intolerable toxic side 
effects). therefore, patients and their 
families continue to wait for the discov-
ery of a compound that will alleviate 
their tragic fear and suffering. 
will the discovery come in form of a 
novel medication that blocks the toxic 
effects of beta-amyloid aggregates? Or  
will it come from advances in our 
knowledge of ad pathology that push 
our focus beyond beta-amyloid and  
its toxic aggregation? For now, it is 
impossible to predict it with much 
certainty. i nevertheless remain opti-
mistic that the spirit and commitment 
i encountered within the ad research 
community when i entered it in  
2007 is stronger than ever and will  
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Figure 6. Three paths to beta-amyloid aggregation in Sporadic Alzeimer’s Disease (Author’s scheme).
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